Unknown

Dataset Information

0

Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial.


ABSTRACT: Reducing low-density lipoprotein cholesterol (LDL-C) is associated with reduced risk for major coronary events. Despite statin efficacy, a considerable proportion of statin-treated hypercholesterolemic patients fail to reach therapeutic LDL-C targets as defined by guidelines. This study compared the efficacy of ezetimibe added to ongoing statins with doubling the dose of ongoing statin in a population of Taiwanese patients with hypercholesterolemia.This was a randomized, open-label, parallel-group comparison study of ezetimibe 10 mg added to ongoing statin compared with doubling the dose of ongoing statin. Adult Taiwanese hypercholesterolemic patients not at optimal LDL-C levels with previous statin treatment were randomized (N = 83) to ongoing statin + ezetimibe (simvastatin, atorvastatin or pravastatin + ezetimibe at doses of 20/10, 10/10 or 20/10 mg) or doubling the dose of ongoing statin (simvastatin 40 mg, atorvastatin 20 mg or pravastatin 40 mg) for 8 weeks. Percent change in total cholesterol, LDL-C, high-density lipoprotein cholesterol (HDL-C) and triglycerides, and specified safety parameters were assessed at 4 and 8 weeks.At 8 weeks, patients treated with statin + ezetimibe experienced significantly greater reductions compared with doubling the statin dose in LDL-C (26.2% vs 17.9%, p = 0.0026) and total cholesterol (20.8% vs 12.2%, p = 0.0003). Percentage of patients achieving treatment goal was greater for statin + ezetimibe (58.6%) vs doubling statin (41.2%), but the difference was not statistically significant (p = 0.1675). The safety and tolerability profiles were similar between treatments.Ezetimibe added to ongoing statin therapy resulted in significantly greater lipid-lowering compared with doubling the dose of statin in Taiwanese patients with hypercholesterolemia. Studies to assess clinical outcome benefit are ongoing.Registered at ClinicalTrials.gov: NCT00652327.

SUBMITTER: Yu CC 

PROVIDER: S-EPMC3403927 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial.

Yu Chih-Chieh CC   Lai Wen-Ter WT   Shih Kuang-Chung KC   Lin Tsung-Hsien TH   Lu Chieh-Hua CH   Lai Hung-Jen HJ   Hanson Mary E ME   Hwang Juey-Jen JJ  

BMC research notes 20120523


<h4>Background</h4>Reducing low-density lipoprotein cholesterol (LDL-C) is associated with reduced risk for major coronary events. Despite statin efficacy, a considerable proportion of statin-treated hypercholesterolemic patients fail to reach therapeutic LDL-C targets as defined by guidelines. This study compared the efficacy of ezetimibe added to ongoing statins with doubling the dose of ongoing statin in a population of Taiwanese patients with hypercholesterolemia.<h4>Methods</h4>This was a r  ...[more]

Similar Datasets

| S-EPMC8935785 | biostudies-literature
| S-EPMC5903480 | biostudies-literature
| S-EPMC4946327 | biostudies-literature
| S-EPMC2992529 | biostudies-literature
| S-EPMC6779015 | biostudies-literature
| S-EPMC8896700 | biostudies-literature
| S-EPMC8031952 | biostudies-literature
2022-11-27 | GSE189926 | GEO
| S-EPMC7153222 | biostudies-literature